New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
Search Results for
NIH Coaxes Big Biopharma to AMP Up Drug Development
February 4, 2014
biopharmas include AbbVie, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson unit Janssen Research and Development, Merck & Co., Sanofi, and Takeda. ...
Sanford-Burnham Wins $275M Commitment toward Strategic Vision...
January 28, 2014
The institute said it will refine drug candidates through preclinical validation to facilitate stronger partnerships with pharmas, such as those it maintains with Takeda ...
GEN's List of Top Pharma and Biotech Firms
January 15, 2014
(Bayer, Eli Lilly, Novartis, Pfizer, and Sanofi); and the remaining five ranked the same as last year (Astellas, Daiichi Sankyo, Glaxo-SmithKline, Johnson & Johnson, and Takeda). ...